Publications by authors named "Ananya Pathak"
Article Synopsis
- Intravitreal anti-VEGF therapy is a key treatment for retinal diseases, but the effectiveness and safety of new bispecific agents like faricimab compared to traditional monoclonal anti-VEGF agents is still uncertain.
- A systematic review of studies from 2015 to 2024 analyzed outcomes from 13 studies involving both faricimab and standard anti-VEGF therapy, focusing on visual acuity, central subfield thickness, and adverse events.
- Results showed no significant difference in visual acuity between the two treatments, but faricimab reduced central subfield thickness more effectively in cases of diabetic macular edema and retinal vein occlusion, with similar rates of ocular side effects across both agent types.
Background: Cognitive behavioural therapy (CBT) has been shown to be effective for several psychiatric and somatic conditions; however, most randomized controlled trials (RCTs) have administered treatment in person and whether remote delivery is similarly effective remains uncertain. We sought to compare the effectiveness of therapist-guided remote CBT and in-person CBT.
Methods: We systematically searched MEDLINE, Embase, PsycINFO, CINAHL, and the Cochrane Central Register of Controlled Trials from inception to July 4, 2023, for RCTs that enrolled adults (aged ≥ 18 yr) presenting with any clinical condition and that randomized participants to either therapist-guided remote CBT (e.
Intravitreal injections of antiangiogenic agents are pivotal in treating neovascular age-related macular degeneration (nAMD). The comparative efficacy and safety of treat-and-extend (T&E) versus bimonthly, monthly, and pro re nata (PRN) dosing remains unclear. A systematic review and meta-analysis of English-language RCTs reporting on efficacy and/or safety outcomes of dosing regimens of anti-VEGF agents in nAMD was performed.
View Article and Find Full Text PDF